Intranasal azelastine and mometasone exhibit a synergistic effect on a murine model of allergic rhinitis
Conclusion We found that the combination of intranasal azelastine and mometasone synergistically suppressed Th17 responses and (reciprocally) elevated Treg responses. Therefore, this combination not only ameliorated allergic inflammation by suppressing Th2 responses, but also usefully modified the Treg/Th17 balance. (Source: American Journal of Otolaryngology)
Source: American Journal of Otolaryngology - January 17, 2017 Category: Endocrinology Source Type: research
Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies
ConclusionLevocetirizine has modest sedative effects with a risk ratio of 1.67 when compared with placebo. The sedative effects observed for levocetirizine are not different from other second-generation antihistamines. (Source: Drugs)
Source: Drugs - January 8, 2017 Category: Drugs & Pharmacology Source Type: research
The discovery of quinoline based single-ligand human H1 and H3 receptor antagonists.
Abstract
A novel series of potent quinoline-based human H1 and H3 bivalent histamine receptor antagonists, suitable for intranasal administration for the potential treatment of allergic rhinitis associated nasal congestion, were identified. Compound 18b had slightly lower H1 potency (pA2 8.8 vs 9.7 for the clinical goldstandard azelastine), and H3 potency (pKi 9.1vs 6.8 for azelastine), better selectivity over α1A, α1B and hERG, similar duration of action, making 18b a good back-up compound to our previous candidate, but with a more desirable profile.
PMID: 27866818 [PubMed - as supplied by publi...
Source: Bioorganic and Medicinal Chemistry Letters - November 9, 2016 Category: Chemistry Authors: Procopiou PA, Ancliff RA, Gore PM, Hancock AP, Hodgson ST, Holmes DS, Keeling SP, Looker BE, Parr NA, Rowedder JE, Slack RJ Tags: Bioorg Med Chem Lett Source Type: research
Combination therapy in allergic rhinitis: What works and what does not work.
Abstract
Allergic rhinitis and other rhinitis subtypes are increasingly becoming some of the most prevalent and expensive medical conditions that affect the U.S.
POPULATION: Both direct health care costs and indirect costs significantly impact the health care system due to delays in diagnosis, lack of treatment, ineffective treatment, poor medication adherence, and associated comorbidities. Many patients who have AR turn to over-the-counter medications for relief but often find themselves dissatisfied with the results. Determining the correct diagnosis, followed by initiation of the most-effective ...
Source: American Journal of Rhinology and Allergy - October 31, 2016 Category: ENT & OMF Authors: Greiwe JC, Bernstein JA Tags: Am J Rhinol Allergy Source Type: research
A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US
(Source: Journal of Asthma and Allergy)
Source: Journal of Asthma and Allergy - July 11, 2016 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
MP ‐AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children
The objective was to evaluate the efficacy of MP‐AzeFlu (Dymista®) vs fluticasone propionate (FP), (both 1 spray/nostril bid), in children with allergic rhinitis (AR). MP‐AzeFlu combines azelastine hydrochloride, FP and a novel formulation in a single spray. Children were randomized in a 3 : 1 ratio to MP‐AzeFlu or FP in this open‐label, 3‐month study. Efficacy was assessed in children aged ≥ 6 to <12 years (MP‐AzeFlu: n = 264; FP: n = 89), using a 4‐point symptom severity rating scale from 0 to 3 (0 = no symptoms; 3 = severe symptoms). Over the 3‐month period, MP‐AzeFlu‐treated children experienc...
Source: Allergy - May 31, 2016 Category: Allergy & Immunology Authors: W. Berger, J. Bousquet, A. T. Fox, J. Just, A. Muraro, A. Nieto, E. Valovirta, M. Wickman, U. Wahn Tags: Brief Communication Source Type: research
Antioxidant activities of curcumin in allergic rhinitis
Abstract
We investigated the antioxidant effects of curcumin in an experimental rat model of allergic rhinitis (AR). Female Wistar albino rats (n = 34) were divided randomly into four groups: healthy rats (control group, n = 8), AR with no treatment (AR + NoTr group, n = 10), AR with azelastine HCl treatment (AR + Aze group, n = 8), and AR with curcumin treatment (AR + Curc group, n = 8). On day 28, total blood IgE levels were measured. For measurement of antioxidant activity, the glutathione (GSH) level and catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) ac...
Source: European Archives of Oto-Rhino-Laryngology - May 3, 2016 Category: ENT & OMF Source Type: research
Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade
We report the use of the cascade in profiling two small libraries containing clinically tested compounds and identify Clemastine, Azelastine, Ifenprodil, Ziprasidone and Clofibrate as molecules having appropriate profiles. Analysis of clinical derived pharmacokinetic and toxicity data indicates that none of these are appropriate for repurposing but they may represent suitable start points for further optimisation for the treatment of Chagas disease. (Source: PLoS Neglected Tropical Diseases)
Source: PLoS Neglected Tropical Diseases - April 14, 2016 Category: Tropical Medicine Authors: Manu De Rycker Source Type: research
MP‐AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children
This article is protected by copyright. All rights reserved. (Source: Allergy)
Source: Allergy - March 31, 2016 Category: Allergy & Immunology Authors: William Berger, Jean Bousquet, Adam T Fox, Jocelyn Juste, Antonella Muraro, Antonio Nieto, Erkka Valovirta, Magnus Wickman, Ulrich Wahn Tags: Brief Communication Source Type: research
Antihistamines for the Treatment of Allergic Rhino-conjunctivitis
Opinion statement
Histamine plays an important role in the pathogenesis of allergic rhino-conjunctivitis (ARC). First generation antihistamines are sedative, they cause cognitive and psychomotor impairment, and they are not indicated for the treatment of ARC. Second generation H1-antihistamines, with their improved safety profile and faster and longer duration of action, meet many of the ARIA (Allergic Rhinitis and its Impact on Asthma) optimal antihistamine prerequisites for the treatment of ARC. They are recommended as first line therapy for the treatment of children and adults with ARC and are efficaci...
Source: Current Treatment Options in Allergy - March 15, 2016 Category: Allergy & Immunology Source Type: research
Intranasal spray shows efficacy when children rated their own allergic rhinitis symptoms
Researchers have found that a combination intranasal spray containing azelastine hydrochloride and fluticasone propionate produces a significant reduction in symptoms of seasonal allergic rhinitis when children rated their own symptoms, rather than their caregivers. (Source: The Pharmaceutical Journal)
Source: The Pharmaceutical Journal - March 14, 2016 Category: Drugs & Pharmacology Source Type: research
Efficacy of MP‐AzeFlu in children with seasonal allergic rhinitis: Importance of paediatric symptom assessment
ConclusionsMP‐AzeFlu is an effective treatment for AR in childhood. Caregivers are less able than children to accurately assess response to treatment with available tools. A simple paediatric‐specific tool to assess efficacy in AR trials in children is needed. (Source: Pediatric Allergy and Immunology)
Source: Pediatric Allergy and Immunology - March 1, 2016 Category: Allergy & Immunology Authors: William Berger, Eli O. Meltzer, Niran Amar, Adam T. Fox, Jocelyne Just, Antonella Muraro, Antonio Nieto, Erkka Valovirta, Magnus Wickman, Jean Bousquet Tags: Original Article Source Type: research
Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis.
Authors: Klimek L, Bousquet J, Price D
Abstract
INTRODUCTION: As a chronic disease, allergic rhinitis (AR) requires regular use of allergy medications for the effective management of symptoms. It is therefore imperative that AR treatments not only provide adequate symptom control but are also well tolerated.
AREAS COVERED: MP29-02 (Dymista, Meda, Solna, Sweden) is the first new class of AR medication (WHO ATC R01AD58) since the introduction of intranasal corticosteroids (INS) almost 50 years ago. It is a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate delivered ...
Source: Expert Opinion on Drug Safety - February 17, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu.
Authors: Klimek L, Demoly P, Price D
Abstract
For any allergic rhinitis (AR) treatment, it is crucial to provide evidence not only of efficacy (assessed in randomized controlled trials (RCTs)) but also of effectiveness in real-life. Observational studies provide valuable data on the use and results associated with interventions prescribed in real-life. However, real-life evidence supporting available AR treatment options is sparse with effectiveness only established for oral antihistamines (desloratadine, ebastine), intranasal corticosteroids (mometasone furoate, fluticasone propionate (FP)), allergen immu...
Source: Expert Review of Clinical Pharmacology - February 14, 2016 Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research
Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis.
Authors: Klimek L, Mullol J, Hellings P, Gevaert P, Mösges R, Fokkens W
Abstract
INTRODUCTION: Allergic rhinitis (AR) has a major negative impact on patients' quality of life (QoL) and carries a high socio-economic burden. This is particularly the case for patients who experience symptoms for extended periods of time (i.e. those with perennial (PAR) or persistent AR (PER), depending on the classification system used). This review covers available pharmacological advances and recent developments in the treatment of PAR or PER. Areas covered: Pharmacological AR treatment is used to reduce symptom burden and...
Source: Expert Opinion on Pharmacotherapy - February 14, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
